Fernando Caravaggio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fernando Caravaggio has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Ariel Graff-Guerrero
Centre for Addiction and Mental Health
16 shared publications - Philip Gerretsen
Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Canada
13 shared publications - Shinichiro Nakajima
Department of Neuropsychiatry, Keio University School of Medicine, Japan
12 shared publications Gary Remington
Department of Psychiatry, University of Toronto, Toronto, Canada
11 shared publicationsAriel Graff-Guerrero
Department of Psychiatry, University of Toronto, Toronto, Canada
10 shared publications- Eric Plitman
McGill University
10 shared publications
Latest Publications
- 6 April 2026
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (2) , 119
Reduced cerebral blood flow in obstructive sleep apnea: A meta-analysis of SPECT and MRI studies
- 6 April 2026
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (2) , 119
Reduced cerebral blood flow in obstructive sleep apnea: A meta-analysis of SPECT and MRI studies
Measuring Alcohol‐Induced Striatal Dopamine Release in Healthy Humans With [11C]‐Raclopride: A Meta‐Analysis
Alcohol consumption is known to affect dopamine (DA) release in the brain, with significant implications for understanding addiction and its neurobiological underpinnings. This meta‐analysis examined the effects of acute alcohol administration on striatal DA release in healthy humans as measured with [11C]‐raclopride positron emission tomography (PET). Oral alcohol administration was associated with a significant reduction in [11C]‐raclopride binding potential (BPND) in the ventral striatum (Cohen's d = –0.76), indicative of increased DA release, particularly at lower blood alcohol concentration (BAC) levels (0.08 gm%; Z = 2.34, p = 0.02). That oral alcohol may increase DA release in the ventral striatum at lower doses, and decrease DA release at higher doses, warrants further investigation but appears consistent with other known biphasic, hermetic dose–response effects of alcohol. Additionally, larger effect‐sizes in the ventral striatum were observed among those studies which sampled more males than females (Z = –2.08, p = 0.04). While oral alcohol administration was associated with reduced [11C]‐raclopride BPND in the caudate (Cohen's d = –0.39) and putamen (Cohen's d = –0.37), these findings in the dorsal striatum were more variable and less robust. Our analyses suggests that study design (i.e., counterbalanced versus fixed order) may moderate effect sizes observed in the putamen across studies (Z = –2.27, p = 0.02). By identifying gaps in the current literature and proposing directions for future research, this study hopes to inform the design of future PET studies aimed at quantifying alcohol‐induced dopamine release in the striatum of humans.
Measuring Alcohol‐Induced Striatal Dopamine Release in Healthy Humans With [11C]‐Raclopride: A Meta‐Analysis
Alcohol consumption is known to affect dopamine (DA) release in the brain, with significant implications for understanding addiction and its neurobiological underpinnings. This meta‐analysis examined the effects of acute alcohol administration on striatal DA release in healthy humans as measured with [11C]‐raclopride positron emission tomography (PET). Oral alcohol administration was associated with a significant reduction in [11C]‐raclopride binding potential (BPND) in the ventral striatum (Cohen's d = –0.76), indicative of increased DA release, particularly at lower blood alcohol concentration (BAC) levels (0.08 gm%; Z = 2.34, p = 0.02). That oral alcohol may increase DA release in the ventral striatum at lower doses, and decrease DA release at higher doses, warrants further investigation but appears consistent with other known biphasic, hermetic dose–response effects of alcohol. Additionally, larger effect‐sizes in the ventral striatum were observed among those studies which sampled more males than females (Z = –2.08, p = 0.04). While oral alcohol administration was associated with reduced [11C]‐raclopride BPND in the caudate (Cohen's d = –0.39) and putamen (Cohen's d = –0.37), these findings in the dorsal striatum were more variable and less robust. Our analyses suggests that study design (i.e., counterbalanced versus fixed order) may moderate effect sizes observed in the putamen across studies (Z = –2.27, p = 0.02). By identifying gaps in the current literature and proposing directions for future research, this study hopes to inform the design of future PET studies aimed at quantifying alcohol‐induced dopamine release in the striatum of humans.
- 20 April 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (7) , 2950-2967
Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third of patients do not show adequate improvement in positive symptoms with non-clozapine antipsychotics. Additionally, approximately half of them show poor response to clozapine, electroconvulsive therapy, or other augmentation strategies. However, the development of novel treatment for these conditions is difficult due to the complex and heterogenous pathophysiology of treatment-resistant schizophrenia (TRS). Therefore, this review provides key findings, potential treatments, and a roadmap for future research in this area. First, we review the neurobiological pathophysiology of TRS, particularly the dopaminergic, glutamatergic, and GABAergic pathways. Next, the limitations of existing and promising treatments are presented. Specifically, this article focuses on the therapeutic potential of neuromodulation, including electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and deep brain stimulation. Finally, we propose multivariate analyses that integrate various perspectives of the pathogenesis, such as dopaminergic dysfunction and excitatory/inhibitory imbalance, thereby elucidating the heterogeneity of TRS that could not be obtained by conventional statistics. These analyses can in turn lead to a precision medicine approach with closed-loop neuromodulation targeting the detected pathophysiology of TRS.
- 20 April 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (7) , 2950-2967
Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third of patients do not show adequate improvement in positive symptoms with non-clozapine antipsychotics. Additionally, approximately half of them show poor response to clozapine, electroconvulsive therapy, or other augmentation strategies. However, the development of novel treatment for these conditions is difficult due to the complex and heterogenous pathophysiology of treatment-resistant schizophrenia (TRS). Therefore, this review provides key findings, potential treatments, and a roadmap for future research in this area. First, we review the neurobiological pathophysiology of TRS, particularly the dopaminergic, glutamatergic, and GABAergic pathways. Next, the limitations of existing and promising treatments are presented. Specifically, this article focuses on the therapeutic potential of neuromodulation, including electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and deep brain stimulation. Finally, we propose multivariate analyses that integrate various perspectives of the pathogenesis, such as dopaminergic dysfunction and excitatory/inhibitory imbalance, thereby elucidating the heterogeneity of TRS that could not be obtained by conventional statistics. These analyses can in turn lead to a precision medicine approach with closed-loop neuromodulation targeting the detected pathophysiology of TRS.
- 24 January 2022
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 57, 39-49
The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans
- 24 January 2022
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 57, 39-49
The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans
- 1 January 2022
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 132, 1205-1213
Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis
- 1 January 2022
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 132, 1205-1213
Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis
- 7 December 2021
- Published by Taylor & Francis in Psychology, Health & Medicine
- Vol. 27 (10) , 2113-2125
Anti-vaccination attitudes are associated with less analytical and more intuitive reasoning
Online anti-vaccination rhetoric has produced far reaching negative health consequences. Persons who endorse anti-vaccination attitudes may employ less analytical reasoning when problem solving. Considering limitations in previous research, we used an online web-based survey (n = 760; mean age = 47.69; 388 males, 372 females) to address this question. Analytical reasoning was negatively correlated with anti-vaccination attitudes (r = −.18, p < .0001). This relationship remained significant after statistically controlling for potential confounders, including age, sex, education, and religiosity (r = −.16, p < .0001). We hope that elucidating the cognitive, non-information-based aspects of anti-vaccination attitudes will help to guide effective educational interventions aimed at improving public health in the future.
- 7 December 2021
- Published by Taylor & Francis in Psychology, Health & Medicine
- Vol. 27 (10) , 2113-2125
Anti-vaccination attitudes are associated with less analytical and more intuitive reasoning
Online anti-vaccination rhetoric has produced far reaching negative health consequences. Persons who endorse anti-vaccination attitudes may employ less analytical reasoning when problem solving. Considering limitations in previous research, we used an online web-based survey (n = 760; mean age = 47.69; 388 males, 372 females) to address this question. Analytical reasoning was negatively correlated with anti-vaccination attitudes (r = −.18, p < .0001). This relationship remained significant after statistically controlling for potential confounders, including age, sex, education, and religiosity (r = −.16, p < .0001). We hope that elucidating the cognitive, non-information-based aspects of anti-vaccination attitudes will help to guide effective educational interventions aimed at improving public health in the future.
- 1 September 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 226, 108813
A measure of illness awareness in alcohol use disorder—Alcohol Use Awareness and Insight Scale (AAS)
- 1 September 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 226, 108813
A measure of illness awareness in alcohol use disorder—Alcohol Use Awareness and Insight Scale (AAS)
Measuring amphetamine‐induced dopamine release in humans: A comparative meta‐analysis of [11C]‐raclopride and [11C]‐(+)‐PHNO studies
The radiotracers [11C]‐raclopride and [11C]‐(+)‐PHNO are commonly used to measure differences in amphetamine‐induced dopamine release between healthy persons and persons with neuropsychiatric diseases. As an agonist radiotracer, [11C]‐(+)‐PHNO should theoretically be roughly 2.7 times more sensitive to displacement by endogenous dopamine than [11C]raclopride. To date, only one study has been published comparing the sensitivity of these two radiotracers to amphetamine‐induced dopamine release in healthy persons. Unfortunately, conflicting findings in the literature suggests that the dose of amphetamine they employed (0.3 mg/kg, p.o.) may not reliably reduce [11C]‐raclopride binding in the caudate. Thus, it is unclear whether the preponderance of evidence supports the theory that [11C]‐(+)‐PHNO is more sensitive to displacement by amphetamine in humans than [11C]‐raclopride. In order to clarify these issues, we conducted a comparative meta‐analysis summarizing the effects of amphetamine on [11C]‐raclopride and [11C]‐(+)‐PHNO binding in healthy humans. Our analysis indicates that amphetamine given at 0.3 mg/kg, p.o. does not reliably reduce [11C]‐raclopride binding in the caudate. Second, the greater sensitivity of [11C]‐(+)‐PHNO is evidenced at 0.5 mg/kg, p.o., but not at lower doses of amphetamine. Third, our analysis suggests that [11C]‐(+)‐PHNO may be roughly 1.5 to 2.5 times more sensitive to displacement by amphetamine than [11C]‐raclopride in healthy persons. We recommend that future displacement studies with these radiotracers employ 0.5 mg/kg, p.o. of amphetamine with a dose, post‐scan interval of at least 3 hr. Using this dose of amphetamine, [11C]‐raclopride studies should employ at leastn = 34 participants per group, while [11C]‐(+)‐PHNO studies should employ at leastn = 6 participants per group, in order to be sufficiently powered (80%) to detect changes in radiotracer binding within the caudate.
Measuring amphetamine‐induced dopamine release in humans: A comparative meta‐analysis of [11C]‐raclopride and [11C]‐(+)‐PHNO studies
The radiotracers [11C]‐raclopride and [11C]‐(+)‐PHNO are commonly used to measure differences in amphetamine‐induced dopamine release between healthy persons and persons with neuropsychiatric diseases. As an agonist radiotracer, [11C]‐(+)‐PHNO should theoretically be roughly 2.7 times more sensitive to displacement by endogenous dopamine than [11C]raclopride. To date, only one study has been published comparing the sensitivity of these two radiotracers to amphetamine‐induced dopamine release in healthy persons. Unfortunately, conflicting findings in the literature suggests that the dose of amphetamine they employed (0.3 mg/kg, p.o.) may not reliably reduce [11C]‐raclopride binding in the caudate. Thus, it is unclear whether the preponderance of evidence supports the theory that [11C]‐(+)‐PHNO is more sensitive to displacement by amphetamine in humans than [11C]‐raclopride. In order to clarify these issues, we conducted a comparative meta‐analysis summarizing the effects of amphetamine on [11C]‐raclopride and [11C]‐(+)‐PHNO binding in healthy humans. Our analysis indicates that amphetamine given at 0.3 mg/kg, p.o. does not reliably reduce [11C]‐raclopride binding in the caudate. Second, the greater sensitivity of [11C]‐(+)‐PHNO is evidenced at 0.5 mg/kg, p.o., but not at lower doses of amphetamine. Third, our analysis suggests that [11C]‐(+)‐PHNO may be roughly 1.5 to 2.5 times more sensitive to displacement by amphetamine than [11C]‐raclopride in healthy persons. We recommend that future displacement studies with these radiotracers employ 0.5 mg/kg, p.o. of amphetamine with a dose, post‐scan interval of at least 3 hr. Using this dose of amphetamine, [11C]‐raclopride studies should employ at leastn = 34 participants per group, while [11C]‐(+)‐PHNO studies should employ at leastn = 6 participants per group, in order to be sufficiently powered (80%) to detect changes in radiotracer binding within the caudate.
- 1 September 2020
- Published by Elsevier in Schizophrenia Research
- Vol. 223, 279-288
Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia
- 1 September 2020
- Published by Elsevier in Schizophrenia Research
- Vol. 223, 279-288
Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia